Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot
→ Esperion got a 15% bump on its stock price $ESPR this morning after the biotech reported that the FDA had said it didn’t expect to call an advisory panel together to review the newly accepted NDAs for bempedoic acid (BPA) and their bempedoic acid/ezetimibe combination tablet. Investors saw that as a positive sign for the LDL-lowering therapy. The PDUFA date is February 21. The lack of an ad-com is an “important, incremental positive given the investor controversies surrounding BPA’s safety and the assumption among most investors that an adcom was a foregone conclusion; however we would note, the FDA could still convene an adcom if it feels one is needed at any point during the review process,” Stifel‘s Derek Archila wrote in a note.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
